Impact of COVID‐19 Response on Hepatitis Prevention Care and Treatment: Results From Global Survey of Providers and Program Managers
Jessica Laury, Lindsey Hiebert, John W. Ward – 26 April 2021
Hepatitis C Care and Elimination in Ahtahkakoop Cree Nation: An Indigenous Community‐Led Model
Mamata Pandey, Noreen Reed, Stephanie Konrad, Trisha Campbell, Britin Cote, Tanys Isbister, Vanessa Ahenakew, Patricia Isbister, Jodie Albert, Stuart Skinner – 26 April 2021
Successful Management With Dual Therapy of Lenvatinib and Macitentan for HCC With Portopulmonary Hypertension
Tsuyoshi Ishikawa, Ryo Sasaki, Takashi Matsuda, Issei Saeki, Taro Takami, Yasuaki Wada, Masafumi Yano, Isao Sakaida – 25 April 2021
The Importance of Glycemic Equipoise in NASH
Alina M. Allen, Brent A. Neuschwander‐Tetri – 25 April 2021
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH
Sarah McCarron, Brooke Bathon, Donna M. Conlon, Deepti Abbey, Daniel J. Rader, Katerina Gawronski, Christopher D. Brown, Kim M. Olthoff, Abraham Shaked, Tobias D. Raabe – 25 April 2021
Myelocytomatosis‐Protein Arginine N‐Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma
Yuhong Luo, Yuqing Gao, Weiwei Liu, Yuan Yang, Jie Jiang, Ying Wang, Wei Tang, Shoumei Yang, Lulu Sun, Jie Cai, Xiaozhen Guo, Shogo Takahashi, Kristopher W. Krausz, Aijuan Qu, Lei Chen, Cen Xie, Frank J. Gonzalez – 24 April 2021
Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD
Xia Yang, Dating Sun, Hui Xiang, Sichen Wang, Yongping Huang, Ling Li, Xu Cheng, Hui Liu, Fengjiao Hu, Yanjie Cheng, Tengfei Ma, Manli Hu, Han Tian, Song Tian, Yan Zhou, Peng Zhang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Yufeng Hu, Hongliang Li, Zhi‐Gang She – 23 April 2021
The Future of Quality Improvement for Cirrhosis
Elliot B. Tapper, Neehar D. Parikh – 21 April 2021 – Cirrhosis has a significant and growing impact on public health and patient‐reported outcomes (PROs). The increasing burden of cirrhosis has led to an emphasis on the quality of care with the goal of improving overall outcomes in this high‐risk population. Existing evidence has shown the significant gaps in quality across process measures (eg, hepatocellular carcinoma screening), highlighting the need for consistent measurement and interventions to address the gaps in quality care.
Edging Closer to Commonplace: Assessing the Growth of Living Donor Liver Transplantation in the United States
Seth A. Waits, Neehar D. Parikh – 21 April 2021
Feasibility, Outcomes, and Safety of Telehepatology Services During the COVID‐19 Pandemic
Nipun Verma, Saurabh Mishra, Surender Singh, Rajwant Kaur, Talwinder Kaur, Arka De, Madhumita Premkumar, Sunil Taneja, Ajay Duseja, Meenu Singh, Virendra Singh – 20 April 2021 – Coronavirus disease 2019 (COVID‐19) has hampered health care delivery globally. We evaluated the feasibility, outcomes, and safety of telehepatology in delivering quality care amid the pandemic. A telemedicine setup using smartphones by hepatologists was organized at our tertiary‐care center after pilot testing. Consecutive patients availing telehepatology services were recruited between March and July 2020.